Tazarotene in combination with phototherapy - 09/09/11
Abstract |
Despite the vast array of available therapies for treating psoriasis, there remains a need for safer, more effective treatments. Topical tazarotene has been shown to be effective in treating mild-to-moderate psoriasis without causing the adverse effects, such as mucocutaneous toxicity, hyperostosis, and elevation in serum lipids, often associated with orally administered retinoids. A 2-week pretreatment with tazarotene 0.1% gel once daily, followed by tazarotene plus UVB therapy (tazarotene-UVB) 3 times per week for 10 weeks, was more effective than UVB therapy alone or in combination with vehicle gel in reducing plaque elevation, scaling, and erythema. The tazarotene-UVB treatment was well tolerated, and no phototoxicity was observed. Treatment success, defined as a moderate response or better in psoriatic lesions (ie, ≥ 50% improvement in psoriatic lesions compared with baseline), was achieved within 32 days with the tazarotene-UVB treatment, compared with 67 days with UVB alone or UVB plus vehicle gel. (J Am Acad Dermatol 1998;39:S144-8.)
Le texte complet de cet article est disponible en PDF.Plan
Supported by Allergan Skin Care. |
|
Reprint requests: John Y. Koo, Director, Psoriasis & Skin Treatment Center, UCSF, 515 Spruce Street, San Francisco, CA 94118. |
|
0190-9622/98/$5.00 + 0 16/0/92890 |
Vol 39 - N° 4S
P. S144-S148 - octobre 1998 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?